0 03 eps expected for casi pharmaceuticals inc casi


$-0.03 EPS Expected for CASI Pharmaceuticals, Inc. (CASI)


March 12, 2018 – By Dolores Ford



Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.53, from 1.67 in 2017Q2. It dived, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported.

68 were reported by Wells Fargo & Commerce Mn. Manatuck Hill Partners Ltd Liability has invested 0.01% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Deutsche Natl Bank Ag holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 21 shares. Royal Bankshares Of Canada reported 17,572 shares. California Employees Retirement Systems has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 136,518 shares. Next holds 2 shares or 0% of its portfolio. Massachusetts-based Moors & Cabot Incorporated has invested 0.01% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Natl Bank Of America Corp De reported 1,144 shares. Raymond James Financial Svcs Advsrs stated it has 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Geode Cap Management reported 38,315 shares or 0% of all its holdings. Wellington Shields And Lc invested in 489,984 shares or 0.29% of the stock. Moreover, Everett Harris & Co Ca has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 10,002 shares. Renaissance Technologies Ltd Com stated it has 112,900 shares or 0% of all its holdings. Wellington Shields Management Ltd Liability Com owns 0.17% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 725,348 shares. New York-based Blackrock has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI).

Analysts expect CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report $-0.03 EPS on March, 30.They anticipate $0.02 EPS change or 40.00 % from last quarter’s $-0.05 EPS. After having $-0.03 EPS previously, CASI Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 3.32% or $0.11 during the last trading session, reaching $3.2. About 202,993 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since March 12, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.



CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 5 analyst reports since October 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, September 22 by Maxim Group. The firm has “Buy” rating given on Thursday, October 29 by H.C. Wainwright. The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) earned “Buy” rating by H.C. Wainwright on Tuesday, January 16. The rating was maintained by Maxim Group with “Buy” on Monday, August 14.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $223.69 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

More important recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were published by: Marketwatch.com which released: “CASI Pharmaceuticals Inc.” on May 15, 2017, also Prnewswire.com published article titled: “CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)”, Prnewswire.com published: “CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By …” on October 13, 2017. More interesting news about CASI Pharmaceuticals, Inc. (NASDAQ:CASI) was released by: Streetinsider.com and their article: “CASI Pharma (CASI) Reports Acquisition of ANDA Portfolio From Sandoz Inc.” with publication date: January 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Back To Top